ArticleBMC cancer2025
Adenomyosis and endometrial cancer: determining its role as a biological contributor or incidental coexistence.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between adenomyosis subtypes and concurrent endometrial lesions: a propensity score-matched retrospective study.Frontiers in endocrinology · 2026Article
- Uterine Serous Carcinoma Following the Insertion of Levonorgestrel Intrauterine System: A Case Report and Literature Review.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous studies have explored the histological overlap between endometrial carcinoma and adenomyosis, yet the clinical implications of their co-occurrence remain ambiguous. This study aims to evaluate the impact of adenomyosis on the staging, progression, and prognosis of endometrial cancer.
methodThis retrospective cohort study analyzed 388 endometrial cancer (EC) patients undergone hysterectomy with lymphadenectomy between January 2019 to Decmber 2024 after ethical approval (No.: 2024-KY-0671-001). The diagnostic criterion for adenomyosis was the identification of endometrial glands and stroma infiltrating the myometrium at a depth of ≥ 2.5 mm from the endometrial-myometrial junction. Variables included demographics, surgery type, histopathology, stage, molecular markers, treatment, and survival. Kaplan-Meier and log-rank tests assessed survival. Statistical analysis used Mann-Whitney U and Chi-square tests (P < 0.05). Multivariate Cox regression was unfeasible due to limited recurrence events and disease-free survival outcomes are provided as supplementary material.
resultsAmong 388 EC patients, 73 (18.8%) had adenomyosis and 315 (81.2%) did not. The adenomyosis group was younger (median age 52 vs. 55 years, P = 0.011) and had a lower menopause rate (63% vs. 75.2%, P = 0.049). Adjuvant therapy was less frequent in the adenomyosis group (21.9% vs. 37.8%, P = 0.015), while concurrent endometrial hyperplasia was more common (64.4% vs. 32.4%, P < 0.001). No significant differences were observed in tumor characteristics, complications, TCGA subtypes, or survival outcomes. Median follow-up was 56 months for the adenomyosis group and 61 months for the non-adenomyosis group.
conclusionThis study shows that adenomyosis does not affect tumor progression or survival outcomes, indicating a neutral role in endometrial cancer prognosis. However, the interpretation of survival statistics is limited by the low recurrence rate. Patients with adenomyosis are younger, have a lower menopause rate, and require less adjuvant therapy. The higher prevalence of endometrial hyperplasia suggests a potential link to tumor pathogenesis. Overall, adenomyosis appears to be an incidental co-occurrence rather than a biological contributor to endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.